SCHEMBL4237307

SCHEMBL4237307

O=C(O)N(Cc1ccc(F)cc1)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
NPC1 O15118 1/20 0.54
GLA P06280 1/20 0.54
HTT P42858 1/20 0.54
RAB9A P51151 1/20 0.54
PAX8 Q06710 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MAPK14 Q16539 1/20 0.53
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
BCL2A1 Q16548 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
TSHR P16473 2/20 0.49
GAA P10253 1/20 0.49
TRPM8 Q7Z2W7 1/20 0.49
LTB4R2 Q9NPC1 4/20 0.48
KDM4E B2RXH2 1/20 0.48
TAS2R14 Q9NYV8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10694289 0.86 ALDH1A1 (0.57) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL6831433 0.86 LTB4R2 (0.54) RAB9AMAPK14MEN1KMT2ALTB4R2
SCHEMBL1927016 0.86 ALDH1A1 (0.69) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL14809509 0.84 BCL2A1 (0.51) ALDH1A1MAPK14MEN1KMT2ABCL2A1
SCHEMBL6830331 0.83 HTT (0.55) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL1335750 0.82 MAPK14 (0.54) ALDH1A1MAPK14MEN1KMT2ABCL2A1
SCHEMBL4237595 0.81 CNR2 (0.58) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL4242009 0.81 NPC1 (0.59) ALDH1A1NPC1GLAHTTRAB9A
Carbamic Acid SCHEMBL6468271 0.81 NPC1 (0.62) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL6827496 0.81 RAB9A (0.53) ALDH1A1NPC1GLAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US claimed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP claimed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO claimed
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US disclosed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed
EP-1461336-A2 1-ALKYL-1-AZONIABICYCLO (2.2.2) OCTANE CARBAMATE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-09-29 EP disclosed
WO-2003053966-A2 1-ALKYL-1-AZONIABICYCLO [2.2.2] OCTANE CARBAMATE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012116-A1 Muscarinic Receptor Antagonists CHRM3, CHRM2, CHRM5 ALDH1A1 1806/4885NPC1 1644/4885GLA 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.